Previous 10 | Next 10 |
2024-05-31 08:59:26 ET More on Akeso, Merck, etc. Merck Stock: Still Discounted To Graham P/E Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Merck: The Worst Has Been Avoided (Rating Upgrade) Dividend Roundup: Meta Platfo...
2024-05-31 08:14:52 ET This week's dividend activity included increased payouts from Meta Platforms ( NASDAQ: META ) and BMO Financial ( BMO ) as well as declarations from companies like Merck ( NYSE: MRK ) and Dicks’s Sporting Goods ( DKS ).... Read the...
2024-05-30 15:12:02 ET More on Summit Therapeutics Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript Summit ...
2024-05-29 13:43:45 ET Summary Merck stock is still a buy despite near-record stock prices. Thanks to its growth outlook, its current valuation is still far below the Graham P/E, leaving a wide margin of safety. Its well-balanced business model, top-grossing Keytruda franchise...
2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...
Acceptance based on results from the pivotal Phase 3 CCTG IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Acquisition includes Restoret™, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as a preclinical pipeline targeting retinal diseases Restoret anticipated to enter pivotal study for diabetic macular edema in the secon...
2024-05-29 06:40:33 ET Summary ConocoPhillips is in advanced talks to acquire Marathon Oil in a potential all-stock deal. Merck is set to acquire eye-care startup EyeBio for up to $3 billion. Trading platform Robinhood launches a $1 billion share repurchase program. ...
2024-05-29 04:11:16 ET More on Merck Merck: The Worst Has Been Avoided (Rating Upgrade) Merck Q1: There's Still Room For Growth Merck's Keytruda improves overall survival in high-risk, early-stage breast cancer Merck, Kelun buoyed by phase 3 results for breas...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the third quarter of 2024. Payment will be made on July 8, 2024, to shareholders of re...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 04:59:00 ET Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued picks in this environment, even among top high-quality stocks. And some ...
How one employee's upbringing and career journey have motivated her to fight inequities around the world NORTHAMPTON, MA / ACCESSWIRE / July 16, 2024 / For Priya Agrawal, health equity has been a lifelong concern and a guiding principle in the work she's done across industries. As a young...
Symposia will highlight work to overcome HIV-related stigma and discuss the evolving state of HIV treatment and prevention Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced upcoming data presentations and programming at the 25 th International ...